These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7925774)

  • 21. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism.
    Cashman JD; Eaves AC; Eaves CJ
    Blood; 1994 Sep; 84(5):1534-42. PubMed ID: 8068944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abrogation of radiation injury to human hematopoietic stem cells with tumor necrosis factor-alpha.
    Karkanitsa LV; Komarovskaya ME; Krivenko SI
    Stem Cells; 1997; 15 Suppl 2():95-102. PubMed ID: 9368291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors.
    Massé A; Ramirez LH; Bindoula G; Grillon C; Wdzieczak-Bakala J; Raddassi K; Deschamps de Paillette E; Mencia-Huerta JM; Koscielny S; Potier P; Sainteny F; Carde P
    Blood; 1998 Jan; 91(2):441-9. PubMed ID: 9427696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation.
    Robinson S; Lenfant M; Wdzieczak-Bakala J; Melville J; Riches A
    Cell Prolif; 1992 Nov; 25(6):623-32. PubMed ID: 1457609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines.
    Volkov L; Quéré P; Coudert F; Comte L; Praloran V
    Exp Cell Res; 1996 Feb; 223(1):112-6. PubMed ID: 8635482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. II. Unresponsiveness of isolated adult rat hepatocytes, 3T3, FDC-P2, and K562 cell lines to AcSDKP. Possible involvement of intermediary cell(s) in the mechanism of AcSDKP action.
    Lauret E; Dumenil D; Miyanomae T; Sainteny F
    Exp Hematol; 1989 Dec; 17(11):1081-5. PubMed ID: 2583252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrasting mechanisms of the myeloprotective effects of interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil.
    Neta R; Keller JR; Ali N; Blanchette F; Dubois CM
    Radiat Res; 1996 May; 145(5):624-31. PubMed ID: 8619029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril.
    Chisi JE; Wdzieczak-Bakala J; Riches AC
    Stem Cells; 1997; 15(6):455-60. PubMed ID: 9402658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo.
    Aidoudi S; Guigon M; Drouet V; Caen JP; Han ZC
    Int J Hematol; 1998 Aug; 68(2):145-55. PubMed ID: 9803673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemoregulatory peptide (HP5b) dimer effects on normal and malignant cells in culture.
    Frostad S; Kalland T; Aakvaag A; Laerum OD
    Stem Cells; 1993 Jul; 11(4):303-11. PubMed ID: 8401253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
    Douay L; Hu C; Giarratana MC; Gorin NC
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of the tetrapeptide AcSDKP on normal and leukemic bone marrow].
    Najman A; Bonnet D; Isnard F; Lemoine F; Guigon M
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):279-80. PubMed ID: 8337144
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of beta-interleukin on the content and proliferation of hemopoietic precursor cells in intact and irradiated long-term cultures of the bone marrow].
    Lebedev VG; Moroz BB; Deshevoĭ IuB
    Patol Fiziol Eksp Ter; 2002; (4):2-4. PubMed ID: 12638418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow.
    Slanicka Krieger M; Nissen C; Manz CY; Toksoz D; Lyman SD; Wodnar-Filipowicz A
    Exp Hematol; 1998 May; 26(5):365-73. PubMed ID: 9590652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells.
    Li J; Volkov L; Comte L; Herve P; Praloran V; Charbord P
    Exp Hematol; 1997 Feb; 25(2):140-6. PubMed ID: 9015214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms mediating the inhibitory effect of all-trans retinoic acid on primitive hematopoietic stem cells in human long-term bone marrow culture.
    Sammons J; Ahmed N; Khokher MA; Hassan HT
    Stem Cells; 2000; 18(3):214-9. PubMed ID: 10840075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory peptides in hematopoiesis.
    Guigon M; Bonnet D
    Exp Hematol; 1995 Jun; 23(6):477-81. PubMed ID: 7768302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys: a new synthetic derivative for avoiding dimerization and loss of inhibitory activity.
    Paukovits WR; Hergl A; Schulte-Hermann R
    Mol Pharmacol; 1990 Sep; 38(3):401-9. PubMed ID: 2402229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.